Literature DB >> 18470272

Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations.

Claus G Roehrborn1.   

Abstract

Over the last 20 years, our understanding of the pathophysiology and symptomatology of men with lower urinary tract symptoms (LUTS) has become increasingly more sophisticated. With this increase in sophistication, our utilization of various medical therapies, either alone or in combination, has also increased the understanding of the roles of individual medications, combinations of medications, and the benefits of different types of intervention. The rapid decline of the use of transurethral resection of the prostate (TURP) and other surgical procedures for benign prostatic hyperplasia (BPH) in the 1990s is due in part to the introduction of medical therapy. This article reviews the current state of medical therapy for men with LUTS and highlights its promises and its current limitations.

Entities:  

Keywords:  5-Alpha-reductase inhibitors; Alpha-adrenergic receptor blockers; Benign prostatic hyperplasia; Lower urinary tract symptoms; Medical therapy

Year:  2008        PMID: 18470272      PMCID: PMC2312341     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  35 in total

Review 1.  A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.

Authors:  Christopher R Chapple; Claus G Roehrborn
Journal:  Eur Urol       Date:  2006-02-17       Impact factor: 20.096

Review 2.  Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.

Authors:  Natasha Kyprianou
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

3.  Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

Authors:  P C Walsh; J D Madden; M J Harrod; J L Goldstein; P C MacDonald; J D Wilson
Journal:  N Engl J Med       Date:  1974-10-31       Impact factor: 91.245

4.  The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.

Authors:  H Lepor; G Knapp-Maloney; J Wozniak-Petrofsky
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-08

5.  Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Barton Wachs; Jay M Young; Anne Esler; Gregory D Sides; Bela S Denes
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

6.  Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.

Authors:  Steven A Kaplan; Claus G Roehrborn; Roger Dmochowski; Eric S Rovner; Joseph T Wang; Zhonghong Guan
Journal:  Urology       Date:  2006-08       Impact factor: 2.649

7.  5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.

Authors:  P Boyle; C Roehrborn; R Harkaway; J Logie; J de la Rosette; M Emberton
Journal:  Eur Urol       Date:  2004-05       Impact factor: 20.096

8.  Molecular genetics of steroid 5 alpha-reductase 2 deficiency.

Authors:  A E Thigpen; D L Davis; A Milatovich; B B Mendonca; J Imperato-McGinley; J E Griffin; U Francke; J D Wilson; D W Russell
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

10.  The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

Authors:  C G Roehrborn; J E Oesterling; S Auerbach; S A Kaplan; L K Lloyd; D E Milam; R J Padley
Journal:  Urology       Date:  1996-02       Impact factor: 2.649

View more
  28 in total

Review 1.  Urolift: a New Face of Minimally Invasive Surgical Technique for Benign Prostatic Hyperplasia?

Authors:  Johnson F Tsui; Christopher M Dixon
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

Review 2.  DNA methylation in development and disease: an overview for prostate researchers.

Authors:  Diya B Joseph; Douglas W Strand; Chad M Vezina
Journal:  Am J Clin Exp Urol       Date:  2018-12-20

Review 3.  Evaluation and management of post-transurethral resection of the prostate lower urinary tract symptoms.

Authors:  Bilal Chughtai; Vannita Simma-Chiang; Steven A Kaplan
Journal:  Curr Urol Rep       Date:  2014-09       Impact factor: 3.092

4.  Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Balaji Reddy; Karen Ann McCutcheon; Michael Borofsky; Vikram Narayan; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2019-05-25

Review 5.  Convective Radiofrequency Water Vapor Thermal Therapy with Rezūm System.

Authors:  Sevann Helo; Bradley Holland; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2017-10       Impact factor: 3.092

Review 6.  Cholesterol and benign prostate disease.

Authors:  Michael R Freeman; Keith R Solomon
Journal:  Differentiation       Date:  2011-08-20       Impact factor: 3.880

Review 7.  Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results.

Authors:  Omid Yassaie; Joshua A Silverman; Peter J Gilling
Journal:  Curr Urol Rep       Date:  2017-10-18       Impact factor: 3.092

Review 8.  Follow-up of Temporary Implantable Nitinol Device (TIND) Implantation for the Treatment of BPH: a Systematic Review.

Authors:  Riccardo Bertolo; Cristian Fiori; Daniele Amparore; Francesco Porpiglia
Journal:  Curr Urol Rep       Date:  2018-04-26       Impact factor: 3.092

9.  Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Eu Chang Hwang; Jae Hung Jung; Michael Borofsky; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2019-02-13

10.  Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.

Authors:  Altug Tuncel; Varol Nalcacioglu; Kemal Ener; Yilmaz Aslan; Omur Aydin; Ali Atan
Journal:  World J Urol       Date:  2009-10-24       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.